Abstract Rationale 20 to 40% of patients with Chronic Obstructive Pulmonary Disease (COPD) exhibit Type 2 (T2) inflammation, characterized by elevated blood eosinophil count (BEC). Despite this, the healthcare burden associated with this subpopulation remains poorly understood. The objective of this analysis is to evaluate the impact of BEC on healthcare resource utilization and disease burden among patients with COPD. Methods A descriptive, retrospective, analysis was conducted using real-world data from Optum’s de-identified Market Clarity Data (Optum® Market Clarity). COPD and T2 comorbidities were identified using ICD-10 codes. Patients diagnosed with both asthma and COPD were excluded. T2-high and T2-low subgroups were defined by BEC 300/µL and 100/µL, respectively, over the past 12 months. Results Between October 2015 and March 2024, 3,354,422 patients with available BEC were identified as having COPD. Among these patients, T2-high COPD was seen in 4%. Demographics such as age, gender, body mass index and smoking history (pack-year) were comparable across BEC subgroups. Similarly, the prevalence of comorbidities such as hypertension, diabetes or myocardial infarction as well as Charlson comorbidity index were consistent among subgroups. However, T2 high patients demonstrated higher use of systemic steroids, antibiotics and inhaled medication, particularly ICS containing medication. Furthermore, hospitalizations, emergency room visits, and office/patient clinic visits were more frequent over the last 12 months in the T2 high subgroups compared to other subgroups. Conclusion Patients with T2 high COPD exhibit greater medication use and healthcare resource utilization than those with T2 low patients. These findings highlight the need for closer monitoring and early intervention in this high-risk subgroup. This abstract is funded by: Sanofi
Soumagne et al. (Fri,) studied this question.